Morgan Stanley raised the firm’s price target on Centene (CNC) to $45 from $38 and keeps an Equal Weight rating on the shares. Q4 results were “challenged, but relatively cleaner” than peer Molina Healthcare (MOH), the analyst tells investors. Centene expects stable Medicaid margins in 2026 driven by a trend similar to levels in 2025, which the firm calls “more prudent.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNC:
- Centene price target raised to $49 from $47 at Truist
- Largest borrow rate increases among liquid names
- Centene price target raised to $44 from $43 at Wells Fargo
- DME Capital buys BKV, boosts PG&E in Q4
- Balanced Outlook: Raising Long-Term EPS and Target Price While Medicaid Headwinds Justify a Hold Rating